Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

This study is comparing two diabetes medications — enavogliflozin (an SGLT2 inhibitor) and pioglitazone — to see which does a better job controlling blood sugar and slowing the buildup of plaque in arteries in people with Type 2 diabetes. **You may be eligible if...** - You are between 20 and 80 years old - You have Type 2 diabetes with a moderately elevated HbA1c (7.0–10.5%) - You have been taking metformin (with or without a DPP-4 inhibitor) for at least 3 months - Your BMI is 23 or above and your kidney function is normal **You may NOT be eligible if...** - You have Type 1 diabetes, gestational diabetes, or another type of secondary diabetes - You have had a heart attack or other acute cardiovascular event in the last 3 months - You are pregnant, breastfeeding, or not using contraception - You have liver disease or hepatitis - You have heart failure - You have had cancer in the past 5 years - You use insulin or other blood sugar medications beyond metformin/DPP-4 inhibitors Talk to your doctor to see if this trial is right for you.